Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB

BACKGROUND: To assess the prognostic value of pretreatment serum biomarkers in stage IV non-small-cell lung cancer (NSCLC) patients treated with PD-1 (programmed cell death protein 1) inhibitors and their value as a predictor of benefit. METHODS: We performed a retrospective study including patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jia, Wei, Sheng, Zhao, Tianye, Zhang, Xunlei, Wang, Yilang, Zhang, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357262/
https://www.ncbi.nlm.nih.gov/pubmed/35945957
http://dx.doi.org/10.1155/2022/7137357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357262/
https://www.ncbi.nlm.nih.gov/pubmed/35945957
http://dx.doi.org/10.1155/2022/7137357

Ejemplares similares